Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2018 (2018), Article ID 9713691, 24 pages
https://doi.org/10.1155/2018/9713691
Review Article

Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation

1Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
2Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
3PET Centre, Centre for Medical Imaging, Uppsala University Hospital, 75185 Uppsala, Sweden

Correspondence should be addressed to Irina Velikyan; es.aksimedaka@naykilev.aniri

Received 17 September 2017; Revised 19 November 2017; Accepted 10 December 2017; Published 4 January 2018

Academic Editor: Xiang-Guo Li

Copyright © 2018 Irina Velikyan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Velikyan, “Continued rapid growth in Ga applications: update 2013 to June 2014,” Journal of Labelled Compounds & Radiopharmaceuticals, pp. 99–121, 2015. View at Google Scholar
  2. I. Velikyan, “68Ga-based radiopharmaceuticals: Production and application relationship,” Molecules, vol. 20, no. 7, pp. 12913–12943, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Fani, P. Peitl, and I. Velikyan, “Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms,” Pharmaceuticals, vol. 10, no. 1, article no. 30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Velikyan, “Positron emitting [68Ga]Ga-based imaging agents: Chemistry and diversity,” Medicinal Chemistry, vol. 7, no. 5, pp. 345–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Sörensen, I. Velikyan, D. Sandberg et al., “Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT,” Theranostics, vol. 6, no. 2, pp. 262–271, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Velikyan, “Prospective of 68Ga-Radiopharmaceutical development,” Theranostics, vol. 4, no. 1, pp. 47–80, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Lankinen, T. J. Mäkinen, T. A. Pöyhönen et al., “68Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 352–364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Ujula, M. Huttunen, P. Luoto et al., “Matrix metalloproteinase 9 targeting peptides: Syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model,” Bioconjugate Chemistry, vol. 21, no. 9, pp. 1612–1621, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Autio, T. Ujula, P. Luoto, S. Salomäki, S. Jalkanen, and A. Roivainen, “PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: Comparison with 18F-FDG,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 1918–1925, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Silvola, A. Autio, P. Luoto, S. Jalkanen, and A. Roivainen, “Preliminary evaluation of novel 68Ga-DOTAVAP-PEG-P2 peptide targeting vascular adhesion protein-1,” Clinical Physiology and Functional Imaging, vol. 30, no. 1, pp. 75–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Ujula, S. Salomäki, P. Virsu et al., “Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis,” Nuclear Medicine and Biology, vol. 36, no. 6, pp. 631–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Autio, T. Henttinen, H. J. Sipilä, S. Jalkanen, and A. Roivainen, “Mini-PEG spacering of VAP-1-targeting 68Ga-DOTAVAP-P1 peptide improves PET imaging of inflammation,” EJNMMI Research, vol. 1, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Aalto, A. Autio, E. A. Kiss et al., “Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer,” Blood, vol. 118, no. 13, pp. 3725–3733, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Kumar, D. K. Boddeti, S. G. Evans, F. Roesch, and R. Howman-Giles, “Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection,” Nuclear Medicine and Biology, vol. 38, no. 3, pp. 393–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Petrik, H. Haas, G. Dobrozemsky et al., “68Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: Proof of principle,” Journal of Nuclear Medicine, vol. 51, no. 4, pp. 639–645, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Petrik, H. Haas, M. Schrettl, A. Helbok, M. Blatzer, and C. Decristoforo, “In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging,” Nuclear Medicine and Biology, vol. 39, no. 3, pp. 361–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Petrik, G. M. Franssen, H. Haas et al., “Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 7, pp. 1175–1183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rizzello, D. Di Pierro, F. Lodi et al., “Synthesis and quality control of 68Ga citrate for routine clinical PET,” Nuclear Medicine Communications, vol. 30, no. 7, pp. 542–545, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Nanni, C. Errani, and L. Boriani, “68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results,” Journal of Nuclear Medicine, vol. 51, no. 12, pp. 1932–1936, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. S. Das, A. V. Hall, D. W. Wareham, and K. E. Britton, “Infection imaging with radiopharmaceuticals in the 21st century,” Brazilian Archives of Biology and Technology, vol. 45, no. spe, pp. 25–37, 2002. View at Publisher · View at Google Scholar
  21. A. Signore and A. W. J. M. Glaudemans, “The molecular imaging approach to image infections and inflammation by nuclear medicine techniques,” Annals of Nuclear Medicine, vol. 25, no. 10, pp. 681–700, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Yusa, K. Tateda, A. Ohara, and S. Miyazaki, “New possible biomarkers for diagnosis of infections and diagnostic distinction between bacterial and viral infections in children,” Journal of Infection and Chemotherapy, vol. 23, no. 2, pp. 96–100, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Signore, A. W. J. M. Glaudemans, O. Gheysens, C. Lauri, and O. A. Catalano, “Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory Diseases,” Seminars in Nuclear Medicine, vol. 47, no. 3, pp. 286–303, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Velikyan, “Molecular imaging and radiotherapy: Theranostics for personalized patient management,” Theranostics, vol. 2, no. 5, pp. 424–426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Rösch and R. P. Baum, “Generator-based PET radiopharmaceuticals for molecular imaging of tumours: On the way to THERANOSTICS,” Dalton Transactions, vol. 40, no. 23, pp. 6104–6111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. P. Baum, H. R. Kulkarni, and C. Carreras, “Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms,” Seminars in Nuclear Medicine, vol. 42, no. 3, pp. 190–207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. R. P. Baum and H. R. Kulkarni, “Theranostics: From molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - the bad berka experience,” Theranostics, vol. 2, no. 5, pp. 437–447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Velikyan, “Radionuclides for Imaging and Therapy in Oncology,” Cancer Theranostics, pp. 285–325, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Czernin and W. A. Weber, “Issues and controversies in nuclear medicine. Introduction,” Journal of Nuclear Medicine, vol. 52, no. Supplement 2, pp. 1S–2S, 2011. View at Publisher · View at Google Scholar
  30. S. J. Goldsmith and S. Vallabhajosula, “Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications,” Seminars in Nuclear Medicine, vol. 39, no. 1, pp. 2–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. F. Tsan, “Mechanism of gallium-67 accumulation in inflammatory lesions,” Journal of Nuclear Medicine, vol. 26, no. 1, pp. 88–92, 1985. View at Google Scholar
  32. S. L. Kipper, “Radiolabelled leukocyte imaging of the abdomen,” in Nuclear Medicine Annual, J. Freeman, Ed., pp. 81–126, Raven Press, New York, NY, USA, 1995. View at Google Scholar
  33. F. Jamar, J. Buscombe, A. Chiti et al., “EANM/SNMMI guideline for 18F-FDG use in inflammation and infection,” Journal of Nuclear Medicine, vol. 54, no. 4, pp. 647–658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. C. J. Palestro, “The current role of gallium imaging in infection,” Seminars in Nuclear Medicine, vol. 24, no. 2, pp. 128–141, 1994. View at Publisher · View at Google Scholar · View at Scopus
  35. M. S. Akhtar, M. B. Imran, M. A. Nadeem, and A. Shahid, “Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics,” International Journal of Peptides, vol. 2012, Article ID 965238, 19 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Delbeke and G. M. Segall, “Status of and trends in nuclear medicine in the United States,” Journal of Nuclear Medicine, vol. 52, no. 2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. Silverman, R. E. Coleman, and M. E. Phelps, “A tabulated summary of the FDG PET literature,” Journal of Nuclear Medicine, vol. 42, pp. 1S–93S, 2001. View at Google Scholar
  38. M. J. Lindsay, B. A. Siegel, S. R. Tunis et al., “The National Oncologic PET Registry: Expanded Medicare coverage for PET under coverage with evidence development,” American Journal of Roentgenology, vol. 188, no. 4, pp. 1109–1113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Gemmel, H. Van Den Wyngaert, C. Love, M. M. Welling, P. Gemmel, and C. J. Palestro, “Prosthetic joint infections: radionuclide state-of-the-art imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 5, pp. 892–909, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Sörensen, “How does the patient benefit from clinical PET?” Theranostics, vol. 2, no. 5, pp. 427–436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. S. L. Rice, C. A. Roney, P. Daumar, and J. S. Lewis, “The next generation of positron emission tomography radiopharmaceuticals in oncology,” Seminars in Nuclear Medicine, vol. 41, no. 4, pp. 265–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. L. Wahl, J. M. Herman, and E. Ford, “The Promise and Pitfalls of Positron Emission Tomography and Single-Photon Emission Computed Tomography Molecular Imaging-Guided Radiation Therapy,” Seminars in Radiation Oncology, vol. 21, no. 2, pp. 88–100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. W. J. M. Glaudemans, R. H. J. A. Slart, J. M. Van Dijl, M. Van Oosten, and G. M. Van Dam, “Molecular imaging of infectious and inflammatory diseases: A terra incognita,” Journal of Nuclear Medicine, vol. 56, no. 5, pp. 659–661, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Li, W. Bauer, I. Israel et al., “Targeting p-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: Correlation with in vivo 17.6t mri,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 8, pp. 1661–1667, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Eichendorff, P. Svendsen, D. Bender et al., “Biodistribution and PET Imaging of a Novel [68Ga]-Anti-CD163-Antibody Conjugate in Rats with Collagen-Induced Arthritis and in Controls,” Molecular Imaging and Biology, vol. 17, no. 1, pp. 87–93, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. Z. Zhu, Y. Yin, K. Zheng et al., “Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: A prospective proof-of-concept cohort study,” Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1269–1272, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. J. S. Eo, J. C. Paeng, S. Lee et al., “Angiogenesis imaging in myocardial infarction using 68Ga-NOTA- RGD PET: Characterization and application to therapeutic efficacy monitoring in rats,” Coronary Artery Disease, vol. 24, no. 4, pp. 303–311, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. J. H. Kim, Y.-H. Kim, Y. J. Kim et al., “Quantitative positron emission tomography imaging of angiogenesis in rats with forelimb ischemia using 68Ga-NOTA-c(RGDyK),” Angiogenesis, vol. 16, no. 4, pp. 837–846, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Laitinen, J. Notni, K. Pohle et al., “Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction,” EJNMMI Research, vol. 3, no. 1, pp. 1–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Kiugel, I. Dijkgraaf, V. Kytö et al., “Dimeric [68Ga]DOTA-RGD Peptide Targeting α<inf>v</inf>β<inf>3</inf> Integrin Reveals Extracellular Matrix Alterations after Myocardial Infarction,” Molecular Imaging and Biology, vol. 16, no. 6, pp. 793–801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Grönman, M. Tarkia, T. Kiviniemi et al., “Imaging of αvβ3 integrin expression in experimental myocardial ischemia with [68Ga]NODAGA-RGD positron emission tomography,” Journal of Translational Medicine, vol. 15, no. 1, p. 144, 2017. View at Publisher · View at Google Scholar
  52. J. Haukkala, I. Laitinen, P. Luoto et al., “68Ga-DOTA-RGD peptide: Biodistribution and binding into atherosclerotic plaques in mice,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 12, pp. 2058–2067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Virtanen, A. Autio, R. Siitonen et al., “68Ga-DOTA-Siglec-9 - a new imaging tool to detect synovitis,” Arthritis Research & Therapy, vol. 17, no. 1, article no. 308, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Retamal, J. Sorensen, M. Lubberink et al., “Feasibility of (68) Ga-labeled Siglec-9 peptide for the imaging of acute lung inflammation: a pilot study in a porcine model of acute respiratory distress syndrome,” Am J Nucl Med Mol Imaging, vol. 6, no. 1, pp. 18–31, 2016. View at Google Scholar
  55. J. M. U. Silvola, H. Virtanen, R. Siitonen et al., “Leukocyte trafficking-associated vascular adhesion protein 1 is expressed and functionally active in atherosclerotic plaques,” Scientific Reports, vol. 6, Article ID 35089, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Ahtinen, J. Kulkova, L. Lindholm et al., “68Ga-DOTA-Siglec-9 PET/CT imaging of peri-implant tissue responses and staphylococcal infections,” EJNMMI Research, vol. 4, no. 1, article no. 45, pp. 1–11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Autio, S. Jalkanen, and A. Roivainen, “Nuclear imaging of inflammation: Homing-associated molecules as targets,” EJNMMI Research, vol. 3, no. 1, pp. 1–7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. J. T. Thackeray, T. Derlin, A. Haghikia et al., “Molecular Imaging of the Chemokine Receptor CXCR4 after Acute Myocardial Infarction,” JACC: Cardiovascular Imaging, vol. 8, no. 12, pp. 1417–1426, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. J. S. Schmid, A. Schirbel, A. K. Buck, S. Kropf, H.-J. Wester, and C. Lapa, “Pentixafor-Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression after Ischemic Stroke,” Circulation: Cardiovascular Imaging, vol. 9, no. 9, Article ID e005217, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Zhou, G. Hao, H. Weng et al., “In vivo evaluation of medical device-associated inflammation using a macrophage-specific positron emission tomography (PET) imaging probe,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 7, pp. 2044–2047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. S. A. Kularatne, M.-J. Bélanger, X. Meng et al., “Comparative analysis of folate derived PET imaging agents with [ 18F]-2-fluoro-2-deoxy-d-glucose using a rodent inflammatory paw model,” Molecular Pharmaceutics, vol. 10, no. 8, pp. 3103–3111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Ambrosini, M. Zompatori, F. De Luca et al., “68Ga-DOTANOC PET/CT Allows Somatostatin Receptor Imaging in Idiopathic Pulmonary Fibrosis: Preliminary Results,” Journal of Nuclear Medicine, vol. 51, no. 12, pp. 1950–1955, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Lincke, J. Singer, R. Kluge, O. Sabri, and R. Paschke, “Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies,” Thyroid, vol. 19, no. 4, pp. 381–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Rominger, T. Saam, E. Vogl et al., “In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors,” Journal of Nuclear Medicine, vol. 51, no. 2, pp. 193–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. J. M. Tarkin, F. R. Joshi, N. R. Evans et al., “Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging,” Journal of the American College of Cardiology, vol. 69, no. 14, pp. 1774–1791, 2017. View at Google Scholar
  66. S.-P. Lee, H.-J. Im, S. Kang et al., “Noninvasive imaging of myocardial inflammation in myocarditis using 68Ga-tagged mannosylated human serum albumin positron emission tomography,” Theranostics, vol. 7, no. 2, pp. 413–424, 2017. View at Publisher · View at Google Scholar · View at Scopus
  67. Z. Zha, J. Song, S. R. Choi et al., “68Ga-Bivalent Polypegylated Styrylpyridine Conjugates for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy,” Bioconjugate Chemistry, vol. 27, no. 5, pp. 1314–1323, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Watanabe, M. Ono, S. Iikuni et al., “A 68Ga complex based on benzofuran scaffold for the detection of β-amyloid plaques,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 20, pp. 4834–4837, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Cressier, M. Dhilly, T. T. Cao Pham et al., “Gallium-68 Complexes Conjugated to Pittsburgh Compound B: Radiolabeling and Biological Evaluation,” Molecular Imaging and Biology, vol. 18, no. 3, pp. 334–343, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Satpati, C. Arjun, R. Krishnamohan, G. Samuel, and S. Banerjee, “68Ga-labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection,” Chemical Biology & Drug Design, vol. 87, no. 5, pp. 680–686, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Ebenhan, N. Chadwick, and M. M. Sathekge, “Peptide synthesis, characterization and 68Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT,” Nuclear Medicine and Biology, vol. 41, no. 5, pp. 390–400, 2014. View at Publisher · View at Google Scholar
  72. T. Ebenhan, J. R. Zeevaart, and J. D. Venter, “Preclinical evaluation of 68Ga-labeled 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging,” Journal of Nuclear Medicine, vol. 55, no. 2, pp. 308–314, 2014. View at Publisher · View at Google Scholar
  73. B. B. Mokaleng, T. Ebenhan, S. Ramesh et al., “Synthesis, 68Ga-radiolabeling, and preliminary in vivo assessment of a depsipeptide-derived compound as a potential PET/CT infection imaging agent,” BioMed Research International, vol. 2015, Article ID 284354, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Ebenhan, B. Mokaleng, J. Venter, H. Kruger, J. Zeevaart, and M. Sathekge, “Preclinical Assessment of a 68Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent,” Molecules, vol. 22, no. 9, p. 1403, 2017. View at Publisher · View at Google Scholar
  75. S. Chopra, B. Singh, A. Koul, A. Mishra, and H. Wester, “Synthesis of DOTA conjugated GF-17 and RAWVAWR-NH2 and radiolabeling with 68Ga as a potential PET tracer for infection imaging,” J Nucl Med, vol. 57, Supplement 2, p. 1115, 2016. View at Google Scholar
  76. M. Petrik, H. Haas, P. Laverman et al., “68Ga-triacetylfusarinine C and 68Ga-ferrioxamine e for aspergillus infection imaging: uptake specificity in various microorganisms,” Molecular Imaging and Biology, vol. 16, no. 1, pp. 102–108, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. V. Kumar and D. K. Boddeti, “68Ga-radiopharmaceuticals for PET imaging of infection and inflammation,” Recent Results in Cancer Research, vol. 194, pp. 189–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Vorster, A. Maes, A. Jacobs et al., “Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions,” Annals of Nuclear Medicine, vol. 28, no. 6, pp. 523–530, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Vorster, B. Mokaleng, M. M. Sathekge, and T. Ebenhan, “A modified technique for efficient radiolabeling of 68Ga-citrate from a SnO2-based 68Ge/68Ga generator for better infection imaging,” Hellenic Journal of Nuclear Medicine, vol. 16, no. 3, pp. 193–198, 2013. View at Google Scholar · View at Scopus
  80. S. Salomaeki, J. Kemppainen, U. Hohenthal et al., “Head-to-head comparison of 68Ga-Citrate and 18F-FDG PET/CT for detection of infectious foci in patients with staphylococcus aureus bacteraemia,” Contrast Media & Molecular Imaging, vol. 2017, p. 8, 2017. View at Google Scholar
  81. L. Fass, “Imaging and cancer: a review,” Molecular Oncology, vol. 2, no. 2, pp. 115–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Chopra, L. Shan, W. C. Eckelman et al., “Molecular imaging and contrast agent database (MICAD): Evolution and progress,” Molecular Imaging and Biology, vol. 14, no. 1, pp. 4–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Sánchez-Crespo, P. Andreo, and S. A. Larsson, “Positron flight in human tissues and its influence on PET image spatial resolution,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 1, pp. 44–51, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. H. W. A. M. De Jong, L. Perk, G. W. M. Visser, R. Boellaard, G. A. M. S. Van Dongen, and A. A. Lammertsma, “High resolution PET imaging characteristics of68Ga, 124i and89Zr compared to18F,” in Proceedings of the Nuclear Science Symposium Conference Record, 2005 IEEE, pp. 1624–1627, Puerto Rico, October 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. I. Velikyan, A. Sundin, B. Eriksson et al., “In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass,” Nuclear Medicine and Biology, vol. 37, no. 3, pp. 265–275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. U. Eberlein and M. Lassmann, “Dosimetry of [68Ga]-labeled compounds,” Applied Radiation and Isotopes, vol. 76, pp. 70–74, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. C. Pettinato, A. Sarnelli, M. Di Donna et al., “68Ga-DOTANOC: Biodistribution and dosimetry in patients affected by neuroendocrine tumors,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 72–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. B. P. Burke, G. S. Clemente, and S. J. Archibald, “Recent advances in chelator design and labelling methodology for 68Ga radiopharmaceuticals,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 57, no. 4, pp. 239–243, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. I. Velikyan, U. Rosenström, S. Estrada et al., “Synthesis and preclinical evaluation of 68Ga-labeled collagelin analogs for imaging and quantification of fibrosis,” Nuclear Medicine and Biology, vol. 41, no. 9, pp. 728–736, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. M. F. Ferreira, G. Pereira, J. P. André, and etal C., “Ga[NO2A-N-(α-amino)propionate] chelates: Synthesis and evaluation as potential tracers for 68Ga PET,” Dalton Transactions, vol. 43, no. 21, pp. 8037–8047, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Notni, J. Šimeček, and H.-J. Wester, “Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: Unique characteristics and applications,” ChemMedChem, vol. 9, no. 6, pp. 1107–1115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Simeček, O. Zemek, P. Hermann, J. Notni, and H. J. Wester, “Tailored gallium( III) chelator NOPO: synthesis, characterization, bioconjugation, and application in preclinical Ga-68-PET imaging,” Molecular Pharmaceutics, 2013. View at Publisher · View at Google Scholar
  93. D. Parker, B. P. Waldron, and D. S. Yufit, “Crystallographic and solution NMR structural analyses of four hexacoordinated gallium(iii) complexes based on ligands derived from 6-amino-perhydro-1,4-diazepine,” Dalton Transactions, vol. 42, no. 22, pp. 8001–8008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. B. P. Waldron, D. Parker, C. Burchardt, D. S. Yufit, M. Zimny, and F. Roesch, “Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68,” Chemical Communications, vol. 49, no. 6, pp. 579–581, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Parker and B. P. Waldron, “Conformational analysis and synthetic approaches to polydentate perhydro-diazepine ligands for the complexation of gallium(iii),” Organic & Biomolecular Chemistry, vol. 11, no. 17, pp. 2827–2838, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. I. Velikyan, H. Maecke, and B. Langstrom, “Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature,” Bioconjugate Chemistry, vol. 19, no. 2, pp. 569–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Erchegyi, R. Cescato, B. Waser, J. E. Rivier, and J. C. Reubi, “N-Imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function,” Journal of Medicinal Chemistry, vol. 54, no. 17, pp. 5981–5987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. R. Saha, N. Saha, R. S. Donofrio, and L. L. Bestervelt, “Microbial siderophores: A mini review,” Journal of Basic Microbiology, vol. 53, no. 4, pp. 303–317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. V. Nikolova, S. Angelova, N. Markova, and T. Dudev, “Gallium as a Therapeutic Agent: A Thermodynamic Evaluation of the Competition between Ga3+ and Fe3+ Ions in Metalloproteins,” The Journal of Physical Chemistry B, vol. 120, no. 9, pp. 2241–2248, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. C. R. Chitambar, “Gallium and its competing roles with iron in biological systems,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1863, no. 8, pp. 2044–2053, 2016. View at Publisher · View at Google Scholar · View at Scopus
  101. J. A. Lessa, M. A. Soares, and R. G. dos Santos, “Gallium(III) complexes with 2-acetylpyridine-derived thiosemicarbazones: antimicrobial and cytotoxic effects and investigation on the interactions with tubulin,” BioMetals, vol. 26, pp. 151–165, 2013. View at Publisher · View at Google Scholar
  102. M. van Oosten, M. Hahn, L. M. A. Crane et al., “Targeted imaging of bacterial infections: Advances, hurdles and hopes,” FEMS Microbiology Reviews, vol. 39, no. 6, pp. 892–916, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Vorster, A. Maes, C. V. D. Wiele, and M. Sathekge, “Gallium-68 PET: A Powerful Generator-based Alternative to Infection and Inflammation Imaging,” Seminars in Nuclear Medicine, vol. 46, no. 5, pp. 436–447, 2016. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Kircher and C. Lapa, “Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation,” Current Cardiovascular Imaging Reports, vol. 10, no. 2, article no. 6, 2017. View at Publisher · View at Google Scholar · View at Scopus
  105. D. A. Hammoud, “Molecular imaging of inflammation: Current status,” Journal of Nuclear Medicine, vol. 57, no. 8, pp. 1161–1165, 2016. View at Publisher · View at Google Scholar · View at Scopus
  106. D. R. Brenner, D. Scherer, K. Muir et al., “A review of the application of inflammatory biomarkers in epidemiologic cancer research,” Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 9, pp. 1729–1751, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. M. D. Turner, B. Nedjai, T. Hurst, and D. J. Pennington, “Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1843, no. 11, pp. 2563–2582, 2014. View at Publisher · View at Google Scholar
  108. L. Werner, H. Guzner-Gur, and I. Dotan, “Involvement of CXCR4/CXCR7/CXCL12 interactions in inflammatory bowel disease,” Theranostics, vol. 3, no. 1, pp. 40–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Jalkanen and M. Salmi, “VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 1, pp. 18–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Malviya, F. Galli, I. Sonni, and A. Signore, “Imaging T-lymphocytes in inflammatory diseases: A nuclear medicine approach,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 58, no. 3, pp. 237–257, 2014. View at Google Scholar · View at Scopus
  111. S. Gratz, H. J. Rennen, O. C. Boerman, W. J. Oyen, and P. Burma, “(99 m)Tc-interleukin-8 for imaging acute osteomyelitis,” Journal of Nuclear Medicine, vol. 42, no. 8, pp. 1257–1264, 2001. View at Google Scholar
  112. S. Gratz, H. J. Rennen, O. C. Boerman, W. J. Oyen, and F. H. Corstens, “Rapid imaging of experimental colitis with (99 m)Tc-interleukin-8 in rabbits,” Journal of Nuclear Medicne, vol. 42, no. 6, pp. 917–923, 2001. View at Google Scholar
  113. C. Alkim, H. Alkim, A. R. Koksal, S. Boga, and I. Sen, “Angiogenesis in inflammatory bowel disease,” International Journal of Inflammation, vol. 2015, Article ID 970890, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. I. S. Alam, T. H. Witney, G. Tomasi et al., “Radiolabeled RGD tracer kinetics annotates differential αvβ3 integrin expression linked to cell intrinsic and vessel expression,” Molecular Imaging and Biology, vol. 16, no. 4, pp. 558–566, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Notni, K. Pohle, and H.-J. Wester, “Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of 68Ga-TRAP(RGD)3,” Nuclear Medicine and Biology, vol. 40, no. 1, pp. 33–41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Oxboel, M. Brandt-Larsen, C. Schjoeth-Eskesen et al., “Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors,” Nuclear Medicine and Biology, vol. 41, no. 3, pp. 259–267, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Šimeček, J. Notni, T. G. Kapp, H. Kessler, and H.-J. Wester, “Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of 68Ga-NOPO-c(RGDfK),” Molecular Pharmaceutics, vol. 11, no. 5, pp. 1687–1695, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Trajkovic-Arsic, P. Mohajerani, A. Sarantopoulos et al., “Multimodal molecular imaging of integrin avb3 for in vivo detection of pancreatic cancer,” Journal of Nuclear Medicine, vol. 55, no. 3, pp. 446–451, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Cai and P. S. Conti, “RGD-based PET tracers for imaging receptor integrin α vβ3 expression,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 56, no. 5, pp. 264–279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. I. Dijkgraaf, S. Y. A. Terry, W. J. Mcbride et al., “Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide,” Contrast Media & Molecular Imaging, vol. 8, no. 3, pp. 238–245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. P. A. Knetsch, M. Petrik, C. Rangger et al., “[68Ga]NS3-RGD and [68Ga] Oxo-DO3A-RGD for imaging αvβ3 integrin expression: Synthesis, evaluation, and comparison,” Nuclear Medicine and Biology, vol. 40, no. 1, pp. 65–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. Z. Liu and F. Wang, “Development of RGD-based radiotracers for tumor imaging and therapy: Translating from bench to bedside,” Current Molecular Medicine, vol. 13, no. 10, pp. 1487–1505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. H. Choi, J. H. Phi, J. C. Paeng et al., “Imaging of integrin αvβ3 expression using 68Ga-RGD positron emission tomography in pediatric cerebral infarct,” Molecular Imaging, vol. 12, no. 4, pp. 213–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. H.-J. Yoon, K. W. Kang, I. K. Chun et al., “Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 8, pp. 1534–1543, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. R. P. Baum, H. R. Kulkarni, D. Müller et al., “First-in-human study demonstrating tumor-angiogenesis by PET/CT imaging with 68Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for αvβ3 integrin receptor targeting,” Cancer Biotherapy and Radiopharmaceuticals, vol. 30, no. 4, pp. 152–159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. R. Haubner, A. Finkenstedt, A. Stegmayr et al., “[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 11, pp. 2005–2013, 2016. View at Publisher · View at Google Scholar · View at Scopus
  127. V. López-Rodríguez, C. Galindo-Sarco, F. O. García-Pérez, G. Ferro-Flores, O. Arrieta, and M. A. Ávila-Rodríguez, “PET-based human dosimetry of the dimeric αvβ3 integrin ligand 68Ga-DOTA-E-[c(RGDfK)]2, a potential tracer for imaging tumor angiogenesis,” Journal of Nuclear Medicine, vol. 57, no. 3, pp. 404–409, 2016. View at Publisher · View at Google Scholar · View at Scopus
  128. M. V. Backer, Z. Levashova, V. Patel et al., “Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes,” Nature Medicine, vol. 13, no. 4, pp. 504–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. M. V. Backer, Z. Levashova, R. Levenson, F. G. Blankenberg, and J. M. Backer, “Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins,” Methods in Molecular Biology (Clifton, N.J.), vol. 494, pp. 275–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Eder, A. V. Krivoshein, M. Backer, J. M. Backer, U. Haberkorn, and M. Eisenhut, “ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature,” Nuclear Medicine and Biology, vol. 37, no. 4, pp. 405–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  131. E. Blom, I. Velikyan, A. Monazzam, P. Razifar et al., “Synthesis and characterization of scVEGF-PEG-[ 68Ga]NOTA and scVEGF-PEG-[ 68Ga]DOTA PET tracers,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 54, no. 11, pp. 685–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Gratz, M. Béhé, and O. C. Boerman, “99mTc-E-selectin binding peptide for imaging acute osteomyelitis in a novel rat model,” Nuclear Medicine Communications, vol. 22, no. 9, pp. 1003–1013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  133. S. B. Jensen, M. Käkelä, L. Jødal et al., “Exploring the radiosynthesis and in vitro characteristics of [68Ga]Ga-DOTA-Siglec-9,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 60, no. 9, pp. 439–449, 2017. View at Publisher · View at Google Scholar
  134. B. A. Teicher and S. P. Fricker, “CXCL12 (SDF-1)/CXCR4 pathway in cancer,” Clinical Cancer Research, vol. 16, no. 11, pp. 2927–2931, 2010. View at Publisher · View at Google Scholar
  135. O. Jacobson, I. D. Weiss, D. O. Kiesewetter, J. M. Farber, and X. Chen, “PET of tumor CXCR4 expression with 4-18F-T140,” Journal of Nuclear Medicine, vol. 51, no. 11, pp. 1796–1804, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. A. Aghanejad, A. R. Jalilian, Y. Fazaeli et al., “Synthesis and evaluation of [67Ga]-AMD3100: A novel imaging agent for targeting the chemokine receptor CXCR4,” Scientia Pharmaceutica, vol. 82, no. 1, pp. 29–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. O. Jacobson, I. D. Weiss, L. P. Szajek et al., “PET imaging of CXCR4 using copper-64 labeled peptide antagonist,” Theranostics, vol. 1, pp. 251–262, 2011. View at Publisher · View at Google Scholar
  138. O. Jacobson, I. D. Weiss, L. P. Szajek et al., “Improvement of CXCR4 tracer specificity for PET imaging,” Journal of Controlled Release, vol. 157, no. 2, pp. 216–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. H. J. Wester, U. Keller, M. Schottelius et al., “Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging,” Theranostics, vol. 5, no. 6, pp. 618–630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. E. Gourni, O. Demmer, M. Schottelius et al., “PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent,” Journal of Nuclear Medicine, vol. 52, no. 11, pp. 1803–1810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. O. Demmer, I. Dijkgraaf, U. Schumacher et al., “Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4,” Journal of Medicinal Chemistry, vol. 54, no. 21, pp. 7648–7662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. O. Demmer, E. Gourni, U. Schumacher, H. Kessler, and H.-J. Wester, “PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand,” ChemMedChem, vol. 6, no. 10, pp. 1789–1791, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. U. Hennrich, L. Seyler, M. Schäfer et al., “Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression,” Bioorganic & Medicinal Chemistry, vol. 20, no. 4, pp. 1502–1510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. G. P. C. George, E. Stevens, O. Åberg et al., “Preclinical evaluation of a CXCR4-specific 68Ga-labelled TN14003 derivative for cancer PET imaging,” Bioorganic & Medicinal Chemistry, vol. 22, no. 2, pp. 796–803, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Poty, E. Gourni, P. Désogère et al., “AMD3100: A Versatile Platform for CXCR4 Targeting 68Ga-Based Radiopharmaceuticals,” Bioconjugate Chemistry, vol. 27, no. 3, pp. 752–761, 2016. View at Publisher · View at Google Scholar · View at Scopus
  146. K. Philipp-Abbrederis, K. Herrmann, S. Knop et al., “In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma,” EMBO Molecular Medicine, vol. 7, no. 4, pp. 477–487, 2015. View at Publisher · View at Google Scholar · View at Scopus
  147. Z. Wang, M. Zhang, L. Wang et al., “Prospective study of 68Ga-NOTA-NFB: Radiation dosimetry in healthy volunteers and first application in glioma patients,” Theranostics, vol. 5, no. 8, pp. 882–889, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. I. M. Jackson, P. J. Scott, and S. Thompson, “Clinical Applications of Radiolabeled Peptides for PET,” Seminars in Nuclear Medicine, vol. 47, no. 5, pp. 493–523, 2017. View at Publisher · View at Google Scholar
  149. C. Lapa, T. Reiter, R. A. Werner et al., “[68Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression after Myocardial Infarction,” JACC: Cardiovascular Imaging, vol. 8, no. 12, pp. 1466–1468, 2015. View at Publisher · View at Google Scholar · View at Scopus
  150. C. Rischpler, S. G. Nekolla, H. Kossmann et al., “Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI,” Journal of Nuclear Cardiology, vol. 23, no. 1, pp. 131–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  151. F. Hyafil, J. Pelisek, I. Laitinen et al., “Imaging the Cytokine Receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-Pentixafor for PET,” Journal of Nuclear Medicine, vol. 58, no. 3, pp. 499–506, 2017. View at Publisher · View at Google Scholar · View at Scopus
  152. Y. Yi, “Folate receptor-targeted diagnostics and therapeutics for inflammatory diseases,” Immune Network, vol. 16, no. 6, pp. 337–343, 2016. View at Publisher · View at Google Scholar
  153. C. M. Paulos, M. J. Turk, G. J. Breur, and P. S. Low, “Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis,” Advanced Drug Delivery Reviews, vol. 56, no. 8, pp. 1205–1217, 2004. View at Publisher · View at Google Scholar · View at Scopus
  154. W. Han, R. Zaynagetdinov, F. E. Yull et al., “Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation,” American Journal of Respiratory Cell and Molecular Biology, vol. 53, no. 1, pp. 50–59, 2015. View at Publisher · View at Google Scholar · View at Scopus
  155. B. Kühle, C. Müller, and T. L. Ross, “A Novel 68Ga-Labeled pteroic acid-based PET tracer for tumor imaging via the folate receptor,” Recent Results in Cancer Research, vol. 194, pp. 257–267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. C. Brand, V. A. Longo, M. Groaning, W. A. Weber, and T. Reiner, “Development of a New Folate-Derived Ga-68-Based PET Imaging Agent,” Molecular Imaging and Biology, vol. 19, no. 5, pp. 754–761, 2017. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Fani, X. Wang, G. Nicolas et al., “Development of new folate-based PET radiotracers: Preclinical evaluation of 68Ga-DOTA-folate conjugates,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 1, pp. 108–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. C. J. Mathias, M. R. Lewis, D. E. Reichert et al., “Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals,” Nuclear Medicine and Biology, vol. 30, no. 7, pp. 725–731, 2003. View at Publisher · View at Google Scholar · View at Scopus
  159. S.-M. Kim, N. Choi, S. Hwang et al., “Folate receptor-specific positron emission tomography imaging with folic acid-conjugated tissue inhibitor of metalloproteinase-2,” Bulletin of the Korean Chemical Society, vol. 34, no. 11, pp. 3243–3248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  160. M. Fani, M.-L. Tamma, G. P. Nicolas et al., “In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates,” Molecular Pharmaceutics, vol. 9, no. 5, pp. 1136–1145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  161. C. Müller and R. Schibli, “Prospects in folate receptor-targeted radionuclide therapy,” Frontiers in Oncology, vol. 3, Article ID Article 249, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. A. Jain, A. Mathur, U. Pandey et al., “Synthesis and evaluation of a 68Ga labeled folic acid derivative for targeting folate receptors,” Applied Radiation and Isotopes, vol. 116, pp. 77–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  163. W. Xia, A. R. Hilgenbrink, E. L. Matteson, M. B. Lockwood, J.-X. Cheng, and P. S. Low, “A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages,” Blood, vol. 113, no. 2, pp. 438–446, 2009. View at Publisher · View at Google Scholar · View at Scopus
  164. E. P. Krenning, W. A. P. Breeman, P. P. M. Kooij et al., “Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin,” The Lancet, vol. 1, no. 8632, pp. 242–244, 1989. View at Publisher · View at Google Scholar · View at Scopus
  165. E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker et al., “Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 20, no. 8, pp. 716–731, 1993. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Stahl, G. Meisetschläger, M. Schottelius et al., “[123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: Scintigraphic comparison with [111In]octreotide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 1, pp. 45–52, 2006. View at Publisher · View at Google Scholar · View at Scopus
  167. R. Lebtahi, J. le Cloirec, C. Houzard et al., “Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy,” Journal of Nuclear Medicine, vol. 43, no. 7, pp. 889–895, 2002. View at Google Scholar · View at Scopus
  168. C. Decristoforo, T. Maina, B. Nock, M. Gabriel, P. Cordopatis, and R. Moncayo, “99mTc-demotate 1: First data in tumour patients - Results of a pilot/phase I study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 9, pp. 1211–1219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  169. C. Decristoforo, S. J. Mather, W. Cholewinski, E. Donnemiller, G. Riccabona, and R. Moncayo, “(99m)Tc-EDDA/HYNIC-TOC: A new (99m)Tc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: First clinical results and intra-patient comparison with 111In-labelled octreotide derivatives,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 27, no. 9, pp. 1318–1325, 2000. View at Publisher · View at Google Scholar · View at Scopus
  170. A. Hubalewska-Dydejczyk, K. Fröss-Baron, R. Mikołajczak et al., “99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years' experience,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1123–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  171. M. Bangard, M. Béhé, S. Guhlke et al., “Detection of somatostatin receptor-positive tumours using the new 99mC-tricine-HYNIC-D-Phe1-Tyr3-octreotide: First results in patients and comparison with 111In-DTPA-D-Phe1-octreotide,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 27, no. 6, pp. 628–637, 2000. View at Publisher · View at Google Scholar · View at Scopus
  172. A. Helisch, G. J. Fórster, H. Reber et al., “Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA- Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 10, pp. 1386–1392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  173. M. Henze, J. Schuhmacher, P. Hipp et al., “PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-Octreotide: First results in patients with meningiomas,” Journal of Nuclear Medicine, vol. 42, no. 7, pp. 1053–1056, 2001. View at Google Scholar · View at Scopus
  174. I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG,” Cancer, vol. 112, no. 11, pp. 2447–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. A. Al-Nahhas, “Nuclear medicine imaging of neuroendocrine tumours,” Clinical Medicine, vol. 12, no. 4, pp. 377–380, 2012. View at Publisher · View at Google Scholar
  176. V. Ambrosini, S. Nicolini, P. Caroli et al., “PET/CT imaging in different types of lung cancer: an overview,” European Journal of Radiology, vol. 81, no. 5, pp. 988–1001, 2012. View at Publisher · View at Google Scholar · View at Scopus
  177. V. Ambrosini, D. Campana, P. Tomassetti, and S. Fanti, “68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 1, pp. S52–S60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  178. K. E. Oberg, J.-C. Reubi, D. J. Kwekkeboom, and E. P. Krenning, “Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy,” Gastroenterology, vol. 139, no. 3, pp. 753–753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  179. K. Öberg, “Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?” Endocrine Journal, vol. 42, no. 1, pp. 3-4, 2012. View at Publisher · View at Google Scholar · View at Scopus
  180. R. Srirajaskanthan, I. Kayani, A. M. Quigley, J. Soh, M. E. Caplin, and J. Bomanji, “The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy,” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 875–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  181. A. Kroiss, D. Putzer, and C. Uprimny, “Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 5, pp. 865–873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. M. Naji, C. Zhao, S. J. Welsh et al., “68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours,” Molecular Imaging and Biology, vol. 13, no. 4, pp. 769–775, 2011. View at Publisher · View at Google Scholar · View at Scopus
  183. V. Ambrosini, P. Tomassetti, P. Castellucci et al., “Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 8, pp. 1431–1438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  184. D. Putzer, M. Gabriel, B. Henninger et al., “Bone metastases in patients with neuroendocrine tumor: 68Ga- DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy,” Journal of Nuclear Medicine, vol. 50, no. 8, pp. 1214–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. L. K. Anzola-Fuentes, M. Chianelli, F. Galli et al., “Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with Infliximab: a pilot study,” EJNMMI Research, vol. 6, no. 1, article no. 49, 2016. View at Publisher · View at Google Scholar · View at Scopus
  186. T. Nobashi, Y. Nakamoto, T. Kubo et al., “The utility of PET/CT with 68Ga-DOTATOC in sarcoidosis: comparison with 67Ga-scintigraphy,” Annals of Nuclear Medicine, vol. 30, no. 8, pp. 544–552, 2016. View at Publisher · View at Google Scholar · View at Scopus
  187. C. Boy, T. A. Heusner, T. D. Poeppel et al., “68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: Correlation of sst2 mRNA and SUV max,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 7, pp. 1224–1236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  188. P. Rinne, S. Hellberg, M. Kiugel et al., “Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques,” Molecular Imaging and Biology, vol. 18, no. 1, pp. 99–108, 2016. View at Publisher · View at Google Scholar · View at Scopus
  189. M. Asti, E. Ferrari, S. Croci et al., “Synthesis and characterization of 68Ga-labeled curcumin and curcuminoid complexes as potential radiotracers for imaging of cancer and alzheimers disease,” Inorganic Chemistry, vol. 53, no. 10, pp. 4922–4933, 2014. View at Publisher · View at Google Scholar · View at Scopus
  190. A. Signore, I. Santino, and A. W. J. M. Glaudemans, “In vivo imaging of microorganisms,” Clinical and Translational Imaging, vol. 4, no. 3, pp. 161-162, 2016. View at Publisher · View at Google Scholar · View at Scopus
  191. S. Auletta, F. Galli, C. Lauri, D. Martinelli, I. Santino, and A. Signore, “Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review,” Clinical and Translational Imaging, vol. 4, no. 4, pp. 229–252, 2016. View at Publisher · View at Google Scholar · View at Scopus
  192. X. Ning, S. Lee, Z. Wang et al., “Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity,” Nature Materials, vol. 10, no. 8, pp. 602–607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. J. Ady and Y. Fong, “Imaging for infection: From visualization of inflammation to visualization of microbes,” Surgical Infections, vol. 15, no. 6, pp. 700–707, 2014. View at Publisher · View at Google Scholar · View at Scopus
  194. J. M. Sierra, D. Rodriguez-Puig, A. Soriano, J. Mensa, C. Piera, and J. Vila, “Accumulation of 99mTc-ciprofloxacin in Staphylococcus aureus and Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 7, pp. 2691-2692, 2008. View at Publisher · View at Google Scholar · View at Scopus
  195. D. I. Andersson and D. Hughes, “Microbiological effects of sublethal levels of antibiotics,” Nature Reviews Microbiology, vol. 12, no. 7, pp. 465–478, 2014. View at Publisher · View at Google Scholar · View at Scopus
  196. N. Dumarey, D. Blocklet, T. Appelboom, L. Tant, and A. Schoutens, “Infecton is not specific for bacterial osteo-articular infective pathology,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 29, no. 4, pp. 530–535, 2002. View at Publisher · View at Google Scholar · View at Scopus
  197. K. E. Britton, D. W. Wareham, S. S. Das et al., “Imaging bacterial infection with 99mTc-ciprofloxacin (Infecton),” Journal of Clinical Pathology, vol. 55, no. 11, pp. 817–823, 2002. View at Publisher · View at Google Scholar · View at Scopus
  198. G. Ferro-Flores, M. A. Avila-Rodríguez, and F. O. García-Pérez, “Imaging of bacteria with radiolabeled ubiquicidin by SPECT and PET techniques,” Clinical and Translational Imaging, vol. 4, no. 3, pp. 175–182, 2016. View at Publisher · View at Google Scholar · View at Scopus
  199. P. S. Hiemstra, M. T. van den Barselaar, M. Roest, P. H. Nibbering, and R. van Furth, “Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages,” Journal of Leukocyte Biology, vol. 66, no. 3, pp. 423–428, 1999. View at Google Scholar · View at Scopus
  200. M. S. Akhtar, A. Qaisar, J. Irfanullah et al., “Antimicrobial peptide 99mTc-ubiquicidin 29–41 as human infection-imaging agent: clinical trial,” Journal of Nuclear Medicne, vol. 46, no. 4, pp. 567–573, 2005. View at Google Scholar
  201. M. Assadi, K. Vahdat, I. Nabipour et al., “Diagnostic value of 99mTc-ubiquicidin scintigraphy for osteomyelitis and comparisons with 99mTc-methylene diphosphonate scintigraphy and magnetic resonance imaging,” Nuclear Medicine Communications, vol. 32, no. 8, pp. 716–723, 2011. View at Publisher · View at Google Scholar · View at Scopus
  202. T. Emery, “Exchange of Iron by Gallium in Siderophores,” Biochemistry, vol. 25, no. 16, pp. 4629–4633, 1986. View at Publisher · View at Google Scholar · View at Scopus
  203. M. Petrik, C. Zhai, H. Haas, and C. Decristoforo, “Siderophores for molecular imaging applications,” Clinical and Translational Imaging, vol. 5, no. 1, pp. 15–27, 2017. View at Publisher · View at Google Scholar · View at Scopus
  204. H. J. Flint, E. A. Bayer, M. T. Rincon, R. Lamed, and B. A. White, “Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis,” Nature Reviews Microbiology, vol. 6, no. 2, pp. 121–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  205. G. Gowrishankar, M. Namavari, E. B. Jouannot et al., “Investigation of 6-[18F]-fluoromaltose as a novel PET tracer for imaging bacterial infection,” PLoS ONE, vol. 9, no. 9, Article ID e107951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  206. N. Gholipour, M. Akhlaghi, A. M. Kheirabadi et al., “Chelator-free radiolabeling of dextran with 68Ga for PET studies,” Journal of Radioanalytical and Nuclear Chemistry, vol. 311, no. 3, pp. 1811–1817, 2017. View at Publisher · View at Google Scholar · View at Scopus
  207. C. Bettegowda, C. A. Foss, I. Cheong et al., “Imaging bacterial infections with radiolabeled 1-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)-5-iodouracil,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 102, no. 4, pp. 1145–1150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  208. S. A. Soghomonyan, M. Doubrovin, J. Pike et al., “Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK,” Cancer Gene Therapy, vol. 12, no. 1, pp. 101–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  209. C. Palestro, K. Nichols, S. Sheikh-Fayyaz, S. Dewey, P. Singhal, and K. Bhargava, “Can Gallium-68 PET differentiate acute interstitial nephritis from acute tubular necrosis?” Journal of Nuclear Medicne, vol. 57, Supplement 2, p. 551, 2016. View at Google Scholar
  210. A. J. Morguet, D. L. Munz, V. Ivančević et al., “Immunoscintigraphy using technetium-99m-labeled anti-NCA-95 antigranulocyte antibodies as an adjunct to echocardiography in subacute infective endocarditis,” Journal of the American College of Cardiology, vol. 23, no. 5, pp. 1171–1178, 1994. View at Publisher · View at Google Scholar · View at Scopus
  211. C. van der Laken, O. Boerman, W. Oyen et al., “In Vivo Expression of Interleukin‐1 Receptors during Various Experimentally Induced Inflammatory Conditions,” The Journal of Infectious Diseases, vol. 177, no. 5, pp. 1398–1401, 1998. View at Publisher · View at Google Scholar
  212. C. J. Van Der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. Van De Ven, J. W. M. Van Der Meer, and F. H. M. Corstens, “Scintigraphic detection of infection and inflammation: New developments with special emphasis on receptor interaction,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 25, no. 5, pp. 535–546, 1998. View at Publisher · View at Google Scholar · View at Scopus
  213. C. J. van der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. van de Ven, J. W. M. van der Meer, and F. H. M. Corstens, “Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 25, no. 4, pp. 347–352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  214. C. J. Van Der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. Van De Ven, F. H. M. Corstens, and J. W. M. Ven Der Meer, “The kinetics of radiolabelled interleukin-8 in infection and sterile inflammation,” Nuclear Medicine Communications, vol. 19, no. 3, pp. 271–282, 1998. View at Publisher · View at Google Scholar · View at Scopus
  215. E. Lazzeri, P. Erba, M. Perri et al., “Scintigraphic imaging of vertebral osteomyelitis with 111in-biotin,” The Spine Journal, vol. 33, no. 7, pp. E198–E204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  216. E. Blom, B. Långström, and I. Velikyan, “68Ga-labeling of biotin analogues and their characterization,” Bioconjugate Chemistry, vol. 20, no. 6, pp. 1146–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  217. O. Eriksson, F. Carlsson, E. Blom et al., “Preclinical evaluation of a 68Ga-labeled biotin analogue for applications in islet transplantation,” Nuclear Medicine and Biology, vol. 39, no. 3, pp. 415–421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  218. E. A. Weinstein, A. A. Ordonez, V. P. DeMarco et al., “Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography,” Science Translational Medicine, vol. 6, no. 259, p. 259ra146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  219. K. M. Nielsen, M. H. Kyneb, A. K. O. Alstrup et al., “68Ga-labeled phage-display selected peptides as tracers for positron emission tomography imaging of Staphylococcus aureus biofilm-associated infections: Selection, radiolabelling and preliminary biological evaluation,” Nuclear Medicine and Biology, vol. 43, no. 10, pp. 593–605, 2016. View at Publisher · View at Google Scholar · View at Scopus
  220. T. J. Mäkinen, P. Lankinen, T. Pöyhönen, J. Jalava, H. T. Aro, and A. Roivainen, “Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 11, pp. 1259–1268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  221. J. M. U. Silvola, I. Laitinen, H. J. Sipilä et al., “Uptake of 68gallium in atherosclerotic plaques in LDLR-/-ApoB100/100mice,” EJNMMI Research, vol. 1, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  222. T. A. Wynn, “Cellular and molecular mechanisms of fibrosis,” The Journal of Pathology, vol. 214, no. 2, pp. 199–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  223. T. Derlin, D. Jonigk, J. Bauersachs, and F. M. Bengel, “Molecular Imaging of Chemokine Receptor CXCR4 in Non–Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT: Comparison With 18F-FDG,” Clinical Nuclear Medicine, 2016. View at Publisher · View at Google Scholar · View at Scopus
  224. I. Velikyan, U. Rosenström, T. N. Bulenga, O. Eriksson, and G. Antoni, “Feasibility of multiple examinations using68ga-labelled collagelin analogues: Organ distribution in rat for extrapolation to human organ and whole-body radiation dosimetry,” Pharmaceuticals, vol. 9, no. 2, article no. 31, 2016. View at Publisher · View at Google Scholar · View at Scopus
  225. S. Jadhav, M. Käkelä, J. Mäkilä et al., “Synthesis and in Vivo PET Imaging of Hyaluronan Conjugates of Oligonucleotides,” Bioconjugate Chemistry, vol. 27, no. 2, pp. 391–403, 2016. View at Publisher · View at Google Scholar · View at Scopus
  226. A. Autio, A. Saraste, N. Kudomi et al., “Assessment of blood flow with (68) Ga-DOTA PET in experimental inflammation: a validation study using (15) O-water,” American Journal of Nuclear Medicine and Molecular Imaging, vol. 4, no. 6, pp. 571–579, 2014. View at Google Scholar
  227. G. Davies, A. Rolle, A. Maurer et al., “Towards translational immunoPET/MR imaging of invasive pulmonary aspergillosis: the Humanised Monoclonal Antibody JF5 detects in vivo,” Theranostics, vol. 7, no. 14, pp. 3398–3414, 2017. View at Publisher · View at Google Scholar
  228. D. Goodwin, C. Meares, G. David et al., “Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals,” International Journal of Radiation Applications and Instrumentation. Part B: Nuclear Medicine and Biology, vol. 13, no. 4, pp. 383–391, 1986. View at Publisher · View at Google Scholar
  229. D. A. Goodwin, C. F. Mears, M. McTigue, and G. S. David, “Monoclonal antibody hapten radiopharmaceutical delivery,” Nuclear Medicine Communications, vol. 7, no. 8, pp. 569–580, 1986. View at Publisher · View at Google Scholar · View at Scopus
  230. S. E. Halpern and R. O. Dillman, “Problems associated with radioimmunodetection and possibilities for future solutions,” J Biol Response Mod, vol. 6, no. 3, pp. 235–262, 1987. View at Google Scholar
  231. H. Hong, J. Sun, and W. Cai, “Radionuclide-based cancer imaging targeting the carcinoembryonic antigen,” Biomarker Insights, vol. 3, pp. 435–451, 2008. View at Google Scholar · View at Scopus
  232. G. J. Förster, E. B. Santos, P. M. Smith-Jones, P. Zanzonico, and S. M. Larson, “Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: Strategies for reduction of the renal dose,” Journal of Nuclear Medicine, vol. 47, no. 1, pp. 140–149, 2006. View at Google Scholar · View at Scopus
  233. Z. Yao, M. Zhang, H. Kobayashi et al., “Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase,” Journal of Nuclear Medicine, vol. 36, no. 5, pp. 837–841, 1995. View at Google Scholar · View at Scopus
  234. C-H. Chang, R. M. Sharkey, E. A. Rossi et al., “Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies 1 Supported in part by USPHS Grant R01-CA-84379 from the NIH and Department of Energy Grant DE-FG01-00NE22941 (both to R. M. S.).1,” Mol Cancer Ther, vol. 1, no. 7, pp. 553–563, 2002. View at Google Scholar
  235. R. M. Sharkey, E. A. Rossi, W. J. McBride, C.-H. Chang, and D. M. Goldenberg, “Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy,” Seminars in Nuclear Medicine, vol. 40, no. 3, pp. 190–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  236. R. M. Sharkey, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg, “Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 1, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  237. D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J. Chatal, “Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 823–834, 2006. View at Publisher · View at Google Scholar · View at Scopus
  238. O. C. Boerman, F. G. van Schaijk, W. J. G. Oyen, and F. H. M. Corstens, “Pretargeted radioimmunotherapy of cancer: progress step by step,” Journal of Nuclear Medicine, vol. 44, no. 3, pp. 400–411, 2003. View at Google Scholar
  239. J. Schuhmacher, S. Kaul, G. Klivényi et al., “Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies,” Cancer Research, vol. 61, no. 9, pp. 3712–3717, 2001. View at Google Scholar · View at Scopus
  240. J. Schuhmacher, G. Klivényi, S. Kaul et al., “Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET,” Nuclear Medicine and Biology, vol. 28, no. 7, pp. 821–828, 2001. View at Publisher · View at Google Scholar · View at Scopus
  241. C. Somasundaram, S. Matzku, J. Schuhmacher, and M. Zöller, “Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy,” Cancer Immunology, Immunotherapy, vol. 36, no. 5, pp. 337–345, 1993. View at Publisher · View at Google Scholar · View at Scopus
  242. E. A. Rossi, D. L. Rossi, R. Stein, D. M. Goldenberg, and C.-H. Chang, “A bispecific antibody-IFNα2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells,” Cancer Research, vol. 70, no. 19, pp. 7600–7609, 2010. View at Publisher · View at Google Scholar · View at Scopus
  243. R. M. Sharkey, H. Karacay, S. Litwin et al., “Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody,” Cancer Research, vol. 68, no. 13, pp. 5282–5290, 2008. View at Publisher · View at Google Scholar · View at Scopus
  244. G. L. Griffiths, C.-H. Chang, W. J. McBride et al., “Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates,” Journal of Nuclear Medicine, vol. 45, no. 1, pp. 30–39, 2004. View at Google Scholar · View at Scopus
  245. J. Watine, M. Miédougé, and B. Friedberg, “Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: A systematic review,” Diseases of the Colon & Rectum, vol. 44, no. 12, pp. 1791–1799, 2001. View at Publisher · View at Google Scholar · View at Scopus
  246. M. J. Goldstein and E. P. Mitchell, “Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer,” Cancer Investigation, vol. 23, no. 4, pp. 338–351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  247. D. V. Gold, D. M. Goldenberg, H. Karacay et al., “A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma,” Cancer Research, vol. 68, no. 12, pp. 4819–4826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  248. J. Schuhmacher, G. Klivényi, R. Matys et al., “Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography,” Cancer Research, vol. 55, no. 1, pp. 115–123, 1995. View at Google Scholar · View at Scopus
  249. G. Klivényi, J. Schuhmacher, E. Patzelt et al., “Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44(V6)/anti-gallium chelate antibodies,” Journal of Nuclear Medicine, vol. 39, no. 10, pp. 1769–1776, 1998. View at Google Scholar · View at Scopus
  250. M. Zoller, J. Schuhmacher, J. Reed, W. Maier-Borst, and S. Matzku, “Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET,” Journal of Nuclear Medicine, vol. 33, no. 7, pp. 1366–1372, 1992. View at Google Scholar · View at Scopus
  251. R. M. Sharkey, T. M. Cardillo, E. A. Rossi et al., “Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody,” Nature Medicine, vol. 11, no. 11, pp. 1250–1255, 2005. View at Publisher · View at Google Scholar · View at Scopus
  252. D. M. Goldenberg and R. M. Sharkey, “Novel radiolabeled antibody conjugates,” Oncogene, vol. 26, no. 25, pp. 3734–3744, 2007. View at Publisher · View at Google Scholar · View at Scopus
  253. D. M. Goldenberg, E. A. Rossi, R. M. Sharkey, W. J. McBride, and C.-H. Chang, “Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting,” Journal of Nuclear Medicine, vol. 49, no. 1, pp. 158–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  254. R. Schoffelen, R. M. Sharkey, D. M. Goldenberg et al., “Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a68Ga- And18F-labeled hapten peptide in mice with human tumor xenografts,” Molecular Cancer Therapeutics, vol. 9, no. 4, pp. 1019–1027, 2010. View at Publisher · View at Google Scholar · View at Scopus
  255. E. S. Bos, W. H. Kuijpers, M. Meesters-Winters et al., “In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer,” Cancer Research, vol. 54, no. 13, pp. 3479–3486, 1994. View at Google Scholar
  256. G. Paganelli, M. Bartolomei, M. Ferrari et al., “Pre-Targeted Locoregional Radioimmunotherapy with,” Cancer biotherapy and radiopharmaceuticals, vol. 16, no. 3, pp. 227–235, 2001. View at Publisher · View at Google Scholar
  257. A. Forero, P. L. Weiden, J. M. Vose et al., “Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma,” Blood, vol. 104, no. 1, pp. 227–236, 2004. View at Publisher · View at Google Scholar · View at Scopus
  258. D. M. Goldenberg, C.-H. Chang, E. A. Rossi, W. J. McBride, and R. M. Sharkey, “Pretargeted molecular imaging and radioimmunotherapy,” Theranostics, vol. 2, no. 5, pp. 523–540, 2012. View at Publisher · View at Google Scholar · View at Scopus
  259. H. Karacay, R. M. Sharkey, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg, “Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga,” Journal of Nuclear Medicine, vol. 52, no. 4, pp. 555–559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  260. J. R. Oh and B. C. Ahn, “False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer,” American Journal of Nuclear Medicine and Molecular Imaging, vol. 2, no. 2, pp. 141–150, 2012. View at Google Scholar
  261. E. Frampas, C. Rousseau, C. Bodet-Milin, J. Barbet, J.-F. Chatal, and F. Kraeber-Bodéré, “Improvement of radioimmunotherapy using pretargeting,” Frontiers in Oncology, vol. 3, Article ID 00159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  262. C. S. McKay and M. G. Finn, “Click chemistry in complex mixtures: Bioorthogonal bioconjugation,” Chemistry & Biology, vol. 21, no. 9, pp. 1075–1101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  263. B. L. Oliveira, Z. Guo, and G. J. Bernardes, “Inverse electron demand Diels–Alder reactions in chemical biology,” Chemical Society Reviews, vol. 46, no. 16, pp. 4895–4950, 2017. View at Publisher · View at Google Scholar
  264. B. Nichols, Z. Qin, J. Yang, D. R. Vera, and N. K. Devaraj, “68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers,” Chemical Communications, vol. 50, no. 40, pp. 5215–5217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  265. R. Rossin, P. R. Verkerk, S. M. van den Bosch et al., “In vivo chemistry for pretargeted tumor imaging in live mice,” Angewandte Chemie International Edition, vol. 49, no. 19, pp. 3375–3378, 2010. View at Publisher · View at Google Scholar
  266. B. M. Zeglis, K. K. Sevak, T. Reiner et al., “A pretargeted PET imaging strategy based on bioorthogonal diels-alder click chemistry,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1389–1396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  267. J. L. Houghton, R. Membreno, D. Abdel-Atti et al., “Establishment of the invivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand diels-alder click chemistry,” Molecular Cancer Therapeutics, vol. 16, no. 1, pp. 124–133, 2017. View at Publisher · View at Google Scholar · View at Scopus
  268. J. Funkhouser, “Reinventing pharma: the theranostic revolution,” Current Drug Discovery, pp. 17–19, 2002. View at Google Scholar · View at Scopus
  269. J. Sorensen, I. Velikyan, A. Wennborg et al., “Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, pp. S226–S226, 2014. View at Google Scholar
  270. I. Velikyan, A. Wennborg, J. Feldwisch et al., “GMP compliant preparation of a 68Gallium-labeled Affibody analogue for breast cancer patient examination: first-in-man,” Eur J Nucl Med Mol Imaging, vol. 41, pp. S228–S229, 2014. View at Google Scholar
  271. K. Öberg, “Molecular imaging radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs),” Theranostics, vol. 2, no. 5, pp. 448–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  272. I. Velikyan, A. Wennborg, J. Feldwisch, H. Lindman, J. Carlsson, and J. Sorensen, “Good manufacturing practice production of [ (68) Ga]Ga-ABY-025 for HER2 specific breast cancer imaging,” American Journal of Nuclear Medicine and Molecular Imaging, vol. 6, no. 2, pp. 135–153, 2016. View at Google Scholar
  273. M. Sandström, K. Lindskog, I. Velikyan et al., “Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients,” Journal of Nuclear Medicine, vol. 57, no. 6, pp. 867–871, 2016. View at Publisher · View at Google Scholar · View at Scopus
  274. D. Sandberg, V. Tolmachev, I. Velikyan et al., “Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 8, pp. 1337–1346, 2017. View at Publisher · View at Google Scholar · View at Scopus
  275. H. Zhang, M. A. Moroz, I. Serganova et al., “Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC,” Journal of Nuclear Medicine, vol. 52, no. 1, pp. 123–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  276. M. Naji and A. Al-Nahhas, “68Ga-labelled peptides in the management of neuroectodermal tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 1, pp. S61–S67, 2012. View at Publisher · View at Google Scholar · View at Scopus
  277. I. Velikyan, “The diversity of 68Ga-Based imaging agents,” Recent Results in Cancer Research, vol. 194, pp. 101–131, 2013. View at Publisher · View at Google Scholar · View at Scopus
  278. K. Ferreira, H-Y. Hu, V. Fetz et al., “Multivalent siderophore-dotam conjugates as theranostics for imaging and treatment of bacterial infections,” Angewandte Chemie International Edition, vol. 56, no. 28, pp. 8272–8276, 2017. View at Publisher · View at Google Scholar